Med Chem Res (2017) 26:3072–3075
DOI 10.1007/s00044-017-1978-7

MEDICINAL CHEMISTRY RESEARCH

ERRATUM

# Erratum to: Synthesis and characterization of new *s*-triazine bearing benzimidazole and benzothiazole derivatives as anticancer agents

**G. Jagadeesh Kumar[1,3] · S. Naveen Kumar[1] · Dinesh Thummuri[3] · Lavanya Bindu Sree Adari[3] · V. G. M. Naidu[3] · Kolupula Srinivas[3] · V. Jayathirtha Rao[1,2,3]**

Published online: 17 July 2017


**Erratum to: Med Chem Res (2015) 24:3991–4001**
**DOI 10.1007/s00044-015-1430-9**

The authors regret that the $IC_{50}$ values of compounds **15f**, **15g** and their respective dose response curves in Fig. 1 are incorrect and apologize for any inconvenience caused.

The correct $IC_{50}$ are shown below in the Table 1 and correct dose response curves are displayed in Fig. 1.

The online version of the original article can be found at doi:10.1007/s00044-015-1430-9.

✉ V. G. M. Naidu
vgmnaidu@niperhyd.ac.in

✉ Kolupula Srinivas
ksrinivas07@yahoo.com

✉ V. Jayathirtha Rao
jrao@iict.res.in

[1] Crop Protection Chemicals Division, CSIR-Indian Institute of Chemical Technology, Uppal Road Tarnaka, Hyderabad 500607, India

[2] AcSIR-IICT, CSIR-Indian Institute of Chemical Technology, Uppal Road Tarnaka, Hyderabad 500607, India

[3] National Institute of Pharmaceutical Education and Research, (NIPER), Balanagar, Hyderabad 500037, India




**Fig. 1** Dose response curve of *s*-Triazine derivatives on human cancer cell lines determined by MTT assay after 48 h treatment

**Table 1** Chemical structures of compounds **13a–h** and their inhibitory effects on the growth of human cancer cell lines




| Compound | X | Y | Z | $R_1$ | $IC_{50}$ (μM) | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | MCF-7[a] | MDAMB-231[b] | PC-3[c] | DU-145[d] | HT-29[e] | HGC-27[f] |
| **15a** | NH | H | –NH– | Cl | 12.1 ± 2.6 | 19.9 ± 0.66 | NA | NA | 22.2 ± 2.9 | 11.1 ± 3.8 |
| **15b** | NH | $OCH_3$ | –NH– | Cl | NA | NA | NA | NA | NA | NA |
| **15c** | NH | F | –NH– | Cl | 15.1 ± 1.3 | 17.4 ± 0.2 | NA | NA | 16.0 ± 1.15 | NA |
| **15d** | NH | H | $–NH–CH_2–$ | Cl | NA | NA | NA | NA | NA | NA |
| **16a** | S | H | –NH– | Cl | NA | NA | NA | NA | NA | NA |
| **16b** | S | $OCH_3$ | –NH– | Cl | NA | NA | NA | NA | NA | NA |
| **16c** | S | F | –NH– | Cl | NA | NA | NA | NA | NA | NA |
| **16d** | S | H | $–NH–CH_2–$ | Cl | 14.7 ± 098 | NA | NA | NA | NA | NA |
| **15e** | NH | H | –NH– |  | 4.8 ± 0.5 | 8.3 ± 1.1 | NA | NA | 9.8 ± 0.4 | 15.1 ± 0.2 |
| **15f** | NH | $OCH_3$ | –NH– |  | 1.02 ± 0.01 | 3.12 ± 0.17 | 1.12 ± 0.05 | 1.44 ± 0.05 | 1.35 ± 0.06 | 1.12 ± 0.11 |
| **15g** | NH | F | –NH– |  | 1.04 ± 0.04 | 1.52 ± 0.02 | 0.8 ± 0.02 | 0.95 ± 0.03 | 1.1 ± 0.06 | 0.76 ± 0.01 |
| **15h** | NH | H | $–NH–CH_2–$ |  | 7.02 ± 3.9 | 18.6 ± 3.1 | NA | 20.3 ± 1.6 | 15.6 ± 2.2 | 16.7 ± 0.01 |

**Table 1** continued



| Compound | X | Y | Z | $R_1$ | $IC_{50}$ (μM) | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | MCF-7[a] | MDAMB-231[b] | PC-3[c] | DU-145[d] | HT-29[e] | HGC-27[f] |
| **16e** | S | H | –NH– |  | NA | NA | NA | NA | NA | NA |
| **16f** | S | $OCH_3$ | –NH– |  | NA | NA | NA | NA | NA | NA |
| **16g** | S | F | –NH– |  | NA | NA | NA | NA | NA | NA |
| **16h** | S | H | –NH–$CH_2$– |  | NA | NA | NA | NA | NA | NA |
| **ZSTK474** (Yamaguchi S et al., 2006) | | | | | ND | 10.8 ± 0.2 | 11.7 ± 1.2 | 0.25 ± 0.06 | 25.1 ± 1.1 | 1.11 ± 0.05 |

*NA* not active (Compounds are showing less that 50% cytotoxicity up to 100 μM concentration), *ND* not determined

[a] MCF-7(Breast cancer ER + ve)

[b] MDA-MB 231(TNBC)

[c] PC3 (Prostate)

[d] DU145 (prostate)

[e] HT 29 (Colon cancer)

[f] HGC-27 (Gastric cancer)